Value
9.4/10data confidence 33%| Component | Sub-score |
|---|---|
| EV/EBITDA | 10.0 |
| Analyst target | 9.0 |
- ▸Attractively valued
FTH · Why this verdict
Why Faeth Therapeutics (FTH) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.8/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Faeth Therapeutics sits below the platform's quality floor on cash-burn and Piotroski weakness, but extreme short interest and a wide analyst-implied upside create an asymmetric speculative setup typical of early-stage biotech.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Analysts see 138% upside for Faeth, and the V9 asymmetry ratio of 7.12 clears the platform's 1.5 threshold by a wide margin, reflecting a favorable speculative risk/reward setup. Sentiment breakdown | Analyst-implied upside should stay above 80% and the asymmetry ratio should remain above 3.0 over the next 12 months. | →Stable |
| CounterWith only light analyst coverage, a 138% upside estimate carries wide uncertainty and could be slashed sharply on any negative clinical readout. | ||
Faeth Therapeutics' quality score sits well below the platform's investment floor, driven by negative free cash flow and a weak Piotroski score of 2/9. Bear case | Free cash flow should turn positive, or at minimum burn should narrow, and the Piotroski score should rise above 4 over the next 12 months. | →Stable |
| CounterPre-revenue or early clinical-stage biotech companies are expected to burn cash by design; a low quality or Piotroski score is a poor proxy for a binary-outcome drug developer's actual value. | ||
Short interest sits at an extreme 85% of float, indicating heavy bearish positioning against the stock. Key risks | Short interest should decline from 85% over the next 12 months if the bearish thesis proves wrong. | →Stable |
| CounterExtremely high short interest can also set up a short-squeeze dynamic, where any positive catalyst forces rapid covering and a sharp price spike, a bullish rather than bearish signal in practice. | ||
The stock is overbought (RSI 80) with falling on-balance volume even as price sits above the 200-day moving average, a combination that often precedes a pullback. Momentum breakdown | RSI should cool from 80 toward a more neutral range without price breaking below the 200-day moving average over the next 12 months. | →Stable |
| CounterFalling OBV alongside an overbought RSI is a classic near-term reversal warning that could resolve into a deeper correction rather than a healthy pullback. | ||
Analysts see 138% upside for Faeth, and the V9 asymmetry ratio of 7.12 clears the platform's 1.5 threshold by a wide margin, reflecting a favorable speculative risk/reward setup.
→StableSentiment breakdown
- Expectation
- Analyst-implied upside should stay above 80% and the asymmetry ratio should remain above 3.0 over the next 12 months.
CounterWith only light analyst coverage, a 138% upside estimate carries wide uncertainty and could be slashed sharply on any negative clinical readout.
Faeth Therapeutics' quality score sits well below the platform's investment floor, driven by negative free cash flow and a weak Piotroski score of 2/9.
→StableBear case
- Expectation
- Free cash flow should turn positive, or at minimum burn should narrow, and the Piotroski score should rise above 4 over the next 12 months.
CounterPre-revenue or early clinical-stage biotech companies are expected to burn cash by design; a low quality or Piotroski score is a poor proxy for a binary-outcome drug developer's actual value.
Short interest sits at an extreme 85% of float, indicating heavy bearish positioning against the stock.
→StableKey risks
- Expectation
- Short interest should decline from 85% over the next 12 months if the bearish thesis proves wrong.
CounterExtremely high short interest can also set up a short-squeeze dynamic, where any positive catalyst forces rapid covering and a sharp price spike, a bullish rather than bearish signal in practice.
The stock is overbought (RSI 80) with falling on-balance volume even as price sits above the 200-day moving average, a combination that often precedes a pullback.
→StableMomentum breakdown
- Expectation
- RSI should cool from 80 toward a more neutral range without price breaking below the 200-day moving average over the next 12 months.
CounterFalling OBV alongside an overbought RSI is a classic near-term reversal warning that could resolve into a deeper correction rather than a healthy pullback.
Per-dimension breakdown
Quality
1.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.5 |
| Piotroski F | 2.2 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
8.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.7 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 9.2 |
- ▸Overbought (RSI 85)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
8.0/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.6 |
| Price target | 9.5 |
| erm sentiment | 6.7 |
- ▸Light analyst coverage (6.0) — signal dampened
- ▸Analyst upside: 51%
Insider
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 6.5 |
| insider conviction | 8.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Modest insider buying — $326,127 (0.039% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
Technical
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.3 |
| 52w position | 9.6 |
| gap | 7.0 |
Risk (lower is worse)
0.0/10data confidence 60%| Component | Sub-score |
|---|---|
| short interest | 0.0 |
| days to cover | 0.0 |
| volatility | 0.0 |
- ▸High short interest: 85%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.9/10data confidence 75%| Component | Sub-score |
|---|---|
| erm | 8.0 |
| earnings history | 6.7 |
| surprise avg | 0.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (7)
- MOMENTUM:8.4>=5.5
- ASYMMETRY:2.1>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
2.08
Upside
+31.1%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.8B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects clean gate clearance against Value at 9.4 and asymmetric R:R of 2.08.
The strongest dimensions are Value at 9.4, Momentum at 8.4, and Sentiment at 8.0; the weakest are Risk (lower is worse) at 0.0, Quality at 1.5, and Technical at 4.2. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 2.08 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Quality Below Floor Cash Burn
Trip ifFree cash flow turns positive, or the Piotroski F-Score rises above 4 out of 9 from the current 2, showing the quality floor breach has resolved.
- P2Extreme High Short Interest
Trip ifShort interest falls below 50% of float from the current 85%, showing the bearish positioning has unwound.
- P3Large Analyst Upside Favorable Asymmetry
Trip ifAnalyst upside falls below 40% from the current 138%, or the asymmetry ratio drops below 2.0 from the current 7.12, showing the favorable risk/reward has deteriorated.
- P4Overbought Momentum With Distribution
Trip ifPrice rises more than 10% over the next 3 months while RSI stays above 70, showing the overbought warning failed to predict a pullback.